T nexito plus
Reading File
Finding Sources
Finding Sources
Searching the Web
Nexito Plus escitalopram clonazepam uses dose side effects
Reading File
Reading File
Reading File
Reading Web Page
Nexito Plus escitalopram clonazepam uses dose side effects contraindications
Here is a complete overview of Nexito Plus:
Nexito Plus
Manufacturer: Sun Pharma
Category: Combination antidepressant + anxiolytic
Composition
| Component | Dose per tablet |
|---|---|
| Escitalopram (SSRI) | 5 mg or 10 mg |
| Clonazepam (Benzodiazepine) | 0.5 mg |
Mechanism of Action
Escitalopram (S-citalopram)
Escitalopram is the pure S-enantiomer of citalopram. It is the "quintessential SSRI" - it works by selectively inhibiting the serotonin reuptake transporter (SERT), increasing synaptic serotonin. Unlike racemic citalopram, the removal of the R-enantiomer means:
- No antihistaminic side effects
- No dose-related QTc prolongation at therapeutic doses
- More predictably efficacious at the lowest dose
- Fewest CYP450-mediated drug interactions among SSRIs
(Stahl's Essential Psychopharmacology)
Clonazepam (Benzodiazepine)
Clonazepam is a high-potency, intermediate- to long-acting benzodiazepine. It acts as a positive allosteric modulator of GABA-A receptors, potentiating the inhibitory effect of GABA. This produces:
- Anxiolytic effect
- Anticonvulsant effect
- Muscle relaxation
- Sedation
Peak plasma: 1-4 hours | Half-life: 20-60 hours (mean ~30 hours)
(Maudsley Deprescribing Guidelines)
Indications
- Depression with comorbid anxiety
- Generalized anxiety disorder (GAD)
- Panic disorder
- Social anxiety disorder
The combination is designed for patients who need rapid anxiolysis (clonazepam kicks in quickly) while the SSRI builds up over 2-4 weeks to provide sustained antidepressant and anti-anxiety effects.
Pharmacokinetics of Escitalopram
| Parameter | Value |
|---|---|
| Oral bioavailability | ~80% |
| Time to peak (Tmax) | ~5 hours |
| Protein binding | ~56% |
| Half-life | 27-32 hours |
| Steady-state | ~7 days |
| Metabolism | CYP2C19 (primary), CYP3A4 (minor) |
| Renal clearance | ~7% |
Dose adjustment needed in: elderly (use 10 mg/day max), hepatic impairment (use lower dose).
(Kaplan & Sadock's Comprehensive Textbook of Psychiatry)
Dosage
- Typically taken once daily, with or without food, preferably at the same time each day
- Available in Nexito Plus 5/0.5 mg and Nexito Plus 10/0.5 mg formulations
- Dose is titrated as per clinical response; do not exceed prescribed dose
Side Effects
Common
- Drowsiness / sedation
- Delayed ejaculation
- Low libido / sexual dysfunction
- Nausea, vomiting
- Dizziness
- Headache
- Insomnia or excessive sedation
- Memory impairment / confusion
- Lethargy / fatigue
- Weight changes (gain or loss)
Serious (monitor for)
- Suicidal ideation - especially in young adults early in treatment (black box warning for SSRIs)
- Dependence and withdrawal - clonazepam carries an FDA boxed warning; physical dependence can develop within days to weeks
- Serotonin syndrome - if combined with other serotonergic agents
- Respiratory depression - with alcohol or other CNS depressants
Contraindications
- Concurrent use of MAO inhibitors (risk of serotonin syndrome)
- Pregnancy - generally contraindicated; may harm the fetus
- Breastfeeding - escitalopram passes into breast milk; caution required
- Severe renal/hepatic impairment
- Angle-closure glaucoma (escitalopram risk)
Important Warnings & Precautions
| Situation | Caution |
|---|---|
| Alcohol | Strictly avoid - potentiates CNS depression, worsens dizziness and sedation |
| Driving/machinery | Avoid - clonazepam causes drowsiness and impaired coordination |
| Abrupt discontinuation | Do NOT stop suddenly - risk of benzodiazepine withdrawal (seizures, anxiety) and SSRI discontinuation syndrome |
| Elderly | Use lower doses; increased risk of falls and sedation |
| Kidney disease | Dose adjustment may be required |
| Liver disease | Reduced clearance; use with caution |
Key Drug Interactions
- MAOIs - contraindicated (serotonin syndrome)
- Alcohol / CNS depressants - enhanced sedation and respiratory depression
- CYP2C19 inhibitors (e.g., omeprazole, fluconazole) - increase escitalopram levels
- Other serotonergic drugs (triptans, tramadol, linezolid) - serotonin syndrome risk
- Anticoagulants (warfarin) - SSRIs may increase bleeding risk
Clinical Notes
- The clonazepam component is intended for short-term use (the manufacturer states efficacy data beyond 9 weeks is limited). Long-term combination use is generally not recommended; the SSRI alone should be continued after stabilization.
- Do not stop clonazepam abruptly - taper slowly using hyperbolic dose reductions to minimize withdrawal symptoms (Maudsley Deprescribing Guidelines).
- Nexito Plus should be continued for the full prescribed course even if symptoms improve early.
Sources: Stahl's Essential Psychopharmacology; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Maudsley Prescribing & Deprescribing Guidelines; PharmEasy/1mg drug monographs
Tab Solitin 5mg
Finding Sources
Searching the Web
Solitin 5mg solifenacin succinate uses dose side effects India
Reading File
Reading Web Page
solifenacin Solitin uses dose side effects contraindications mechanism
Reading File
Here is a complete overview of Tab Solitin 5mg:
Tab Solitin 5mg (Solifenacin Succinate)
Generic name: Solifenacin succinate
Brand names in India: Solitin, Soliten, Soliris, Solif
Category: Antimuscarinic / Anticholinergic - Urinary antispasmodic
Manufacturer: Sun Pharma (various)
Composition
| Component | Dose |
|---|---|
| Solifenacin succinate | 5 mg per tablet |
Also available as 10 mg tablet.
Mechanism of Action
Solifenacin succinate (YM905) is a tertiary amine with selective M3 muscarinic receptor antagonism (with modest selectivity for M3 over M2 and M1 receptors). It works by:
- Blocking M3 muscarinic receptors on detrusor (bladder wall) smooth muscle - prevents abnormal involuntary contractions
- Increasing bladder capacity - allows the bladder to hold more urine before the urge to void
- Effects on sensory function - increases the area under the bladder-volume sensation curve, meaning urgency sensations are dampened
The net result is: fewer involuntary bladder contractions, increased voiding intervals, reduced urgency and frequency.
(Campbell-Walsh-Wein Urology)
Pharmacokinetics
| Parameter | Value |
|---|---|
| Bioavailability | ~90% (well absorbed orally) |
| Time to peak (Tmax) | ~3-8 hours |
| Protein binding | ~98% |
| Half-life | 45-68 hours |
| Metabolism | Hepatic - CYP3A4 |
| Elimination | Renal and fecal |
| Steady-state | ~10 days |
The long half-life allows once-daily dosing.
(Campbell-Walsh-Wein Urology)
Indications
- Overactive bladder (OAB) with symptoms of:
- Urinary urgency (sudden, strong urge to urinate)
- Urge urinary incontinence (leakage with urgency)
- Urinary frequency (urinating too often, >8 times/24 hrs)
- Nocturia (waking at night to urinate)
Dosage
| Setting | Dose |
|---|---|
| Standard adult dose | 5 mg once daily |
| If well tolerated and response inadequate | May increase to 10 mg once daily |
| Severe renal impairment (CrCl <30 mL/min) | Maximum 5 mg/day |
| Moderate hepatic impairment | Maximum 5 mg/day |
| Severe hepatic impairment | Contraindicated |
- Take with or without food, swallow whole
- Take at the same time each day
- Maximum benefit seen at 4 weeks; onset of improvement may be sooner
Clinical Efficacy
In large phase III trials, solifenacin 5 mg significantly reduced:
- Micturition frequency (-2.21 micturitions/day vs -1.03 placebo)
- Urgency episodes
- Incontinence episodes
- Volume voided per micturition increased
Solifenacin was non-inferior to tolterodine for micturition frequency but showed significantly greater efficacy for urgency/incontinence. (Campbell-Walsh-Wein Urology)
Side Effects
Common (anticholinergic effects)
- Dry mouth (most common, ~10-28%)
- Constipation
- Nausea, stomach pain, indigestion
- Blurred vision / visual accommodation difficulty
- Urinary retention (less common)
- Drowsiness / fatigue
- Dry eyes
Serious (rare)
- Acute urinary retention - especially in men with BPH
- Angioedema
- QT interval prolongation (at high doses)
- Cognitive impairment (elderly patients - anticholinergic burden)
- Hallucinations / confusion (rare, elderly)
Contraindications
- Urinary retention (current)
- Gastric retention / severe GI motility disorders
- Uncontrolled narrow-angle glaucoma
- Severe hepatic impairment (Child-Pugh C)
- Myasthenia gravis
- Hypersensitivity to solifenacin
Precautions & Warnings
| Situation | Caution |
|---|---|
| Elderly | High anticholinergic burden - risk of falls, cognitive decline, confusion |
| Benign prostatic hyperplasia (BPH) | Risk of urinary retention - use with care |
| Pregnancy | Limited data - use only if clearly necessary |
| Breastfeeding | Excreted in breast milk - avoid |
| Driving | May cause blurred vision and drowsiness - caution |
| Alcohol | Worsens OAB symptoms and may increase CNS effects - avoid |
| Renal impairment | Dose cap at 5 mg/day if severe |
| Hepatic impairment | Dose cap at 5 mg/day if moderate; contraindicated if severe |
Drug Interactions
| Drug | Interaction |
|---|---|
| CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) | Increase solifenacin plasma levels significantly - use with caution or reduce dose |
| CYP3A4 inducers (rifampicin, carbamazepine) | Reduce solifenacin efficacy |
| Other anticholinergics | Additive anticholinergic side effects |
| Mirabegron | Combination used for refractory OAB (evidence-based: SYMPHONY trial) - effective and generally well tolerated |
| QT-prolonging drugs | Additive QT risk - use with caution |
Combination Use
Solifenacin 5 mg + Mirabegron 50 mg (beta-3 agonist) combination has strong evidence for refractory OAB patients who do not respond adequately to monotherapy. This combination works through complementary mechanisms and is endorsed by urology guidelines. (Campbell-Walsh-Wein Urology)
Key Clinical Points
- Take for at least 4 weeks before assessing full benefit
- Do not stop abruptly without consulting your doctor
- Monitor for urinary retention, especially in elderly men
- Due to the anticholinergic burden, use with caution in elderly patients (risk of cognitive decline with long-term use)
- Preferred over older antimuscarinics (oxybutynin) due to better tolerability and selectivity
Sources: Campbell-Walsh-Wein Urology; PharmEasy/Soliten drug monograph
Inj amphoterium B
Finding Sources
Searching the Web
Amphotericin B injection uses dose side effects nephrotoxicity liposomal
You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.